Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
November 4, 2021, 3:23 pm
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14) will showcase continued leadership across both approved and investigational CAR T-cell therapies and medicines.
